Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers

(2018) Joanne Kotsopoulos et al.   JAMA Oncology

Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study

(2017) Ravi F.M. Vermeulen et al.   EUROPEAN JOURNAL OF CANCER

Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?

(2017) S. M. Domchek et al.   JOURNAL OF CLINICAL ONCOLOGY

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study

(2016) Joanne Kotsopoulos et al.   BREAST CANCER RESEARCH AND TREATMENT

2016 IMS Recommendations on women’s midlife health and menopause hormone therapy

(2016) R. J. Baber et al.   CLIMACTERIC

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations

(2016) Catherine A. Shu et al.   JAMA Oncology

Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer

(2015) Ingrid E. Fakkert et al.   EUROPEAN JOURNAL OF CANCER

Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens

(2015) Catheleine M.G. van Driel et al.   MATURITAS

Diagnosis and management of menopause: summary of NICE guidance

(2015) G. Sarri et al.   BMJ-British Medical Journal

Diagnosis and management of menopause: summary of NICE guidance

(2015) G. Sarri et al.   BMJ-British Medical Journal

ACOG Practice Bulletin No. 103: Hereditary Breast and Ovarian Cancer Syndrome

(2014)   OBSTETRICS AND GYNECOLOGY

Progestogens Used in Postmenopausal Hormone Therapy: Differences in Their Pharmacological Properties, Intracellular Actions, and Clinical Effects

(2013) Frank Z. Stanczyk et al.   ENDOCRINE REVIEWS

Risks and benefits of screening asymptomatic women for ovarian cancer: A systematic review and meta-analysis

(2013) Clare J. Reade et al.   GYNECOLOGIC ONCOLOGY

Hereditary gynecologic cancers

(2013) David Mutch et al.   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

Digitized assessment of mammographic breast density – Effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo

(2011) E. Lundström et al.   MATURITAS

Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women

(2010) S. Ziaei et al.   CLIMACTERIC

Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers

(2010) M.J.A. Kenkhuis et al.   MATURITAS

Role of Hormone Therapy in the Management of Menopause

(2010) Jan L. Shifren et al.   OBSTETRICS AND GYNECOLOGY

Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction

(2009) E. A. Nijland et al.   CLIMACTERIC

Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy

(2008) C. A. Gabriel et al.   Familial Cancer

Menopausal Hormone Therapy in BRCA1 Mutation Carriers: Uncertainty and Caution

(2008) R. T. Chlebowski et al.   JNCI-Journal of the National Cancer Institute

Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers

(2008) A. Eisen et al.   JNCI-Journal of the National Cancer Institute

Increased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer Survivors

(2008) L. Holmberg et al.   JNCI-Journal of the National Cancer Institute